VBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent...

Press/Media: Press / Media

PeriodSep 28 2015

Media coverage

35

Media coverage

  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent...
    Media name/outletCNN Money
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletReuters
    CountryUnited Kingdom
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletYahoo! Finance
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletIndividual.com
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletSearchBug
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletVision Monday
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletReliance Trust
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletFinancial Content
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletTown Hall
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletBioSpace
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletA.M. Best
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletWall Street Business Network
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletMoneyShow.com
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletRCL Advisors
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletPettinga Financial Advisors
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletWall Street Select
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletNasdaq
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletMarketplace
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletYahoo! 7 Finance
    CountryAustralia
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outlet4 Traders
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletTamar Securities
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletVirtual Strategy Magazine
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletPipelineReview
    CountrySpain
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletStock Nod
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletU-T San Diego
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletAsk.com
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase
    Media name/outletGood Day Sacramento
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletGlobeNewswire
    CountryUnited States
    Date9/28/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics Reports Full Phase 2 Data From Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM) at the ECC 2015 Conference, Meeting the Primary Endpoint of Statistically-Significant Increase in Overall Survival
    Media name/outletBizWire Express
    CountryIndia
    Date9/28/15
    PersonsAndrew Brenner